Researchers

NISHIO Kazuto

NISHIO Kazuto
Professor/Senior Staff/Dean
Faculty Department of Medicine / Graduate School of Medical Sciences
Researchmap https://researchmap.jp/knishio

Education and Career

Academic & Professional Experience

  • Oct. 2024 - Today , Kindai University Faculty of Medicine Dean
  • Sep. 2023 - Today , Kindai University Faculty of Medicine Department of Medicine 教授
  • 2014 - Today , Kindai University Genomic Center, Life Science Research Institute Director
  • 2006 - Today , Kindai University Faculty of Medicine 教授

Research Activities

Research Areas

  • Life sciences , Respiratory medicine
  • Life sciences , Tumor diagnostics and therapeutics
  • Life sciences , Pharmacology
  • Life sciences , Pharmaceuticals - health and biochemistry
  • Life sciences , Neurosurgery
  • Life sciences , Gastroenterology
  • Life sciences , Obstetrics and gynecology
  • Life sciences , Pathobiochemistry

Research Interests

抗がん剤, チロシンキナーゼ阻害剤, 分子標的薬, アポトーシス, バイオマーカー, 肺癌, 遺伝子発現解析, マイクロアレイ, CD133, 化学療法, ゲフィチニブ, 遺伝子増幅, 細胞周期制御薬, ファルネシルトランスフェラーゼ, がん抑制遺伝子, CD117, 抗腫瘍効果, EGFR, アニーリング, 遺伝子移入

Published Papers

  1. Molecular Characterization of Ovarian Metastases from Colorectal Cancer Using Circulating Tumor DNA Analysis.
    Naoyuki Iwahashi; Tomoko Noguchi; Kazuko Sakai; Tamaki Yahata; Kumiko Nakata; Kaho Nishioka; Megumi Fujino; Shinichiro Takeda; Nobuhiko Suzuki; Kazuto Nishio; Kazuhiko Ino
    JMA journal  9  (4)  , 926-932, 15, Jul. 2026 
  2. Ovarian Epithelioid Tumor With FUS::CREM Fusion in a 63-Year-Old Woman: A Case Report of an Emerging Entity Associated With Systemic Inflammation
    Hiroshi Kajiyama; Yoko Kashima; Tomoyuki Otani; Kazuko Sakai; Naoki Shiraishi; Kazuto Nishio; Yukiko Shishido-Hara; Akihiko Ito; Sachiko Minamiguchi; Noriomi Matsumura
    International Journal of Gynecological Pathology  45  (4)  , 311-317, Jul. 2026 
  3. Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study.
    Yuki Shin; Akitaka Makiyama; Teppei Yamada; Tomomi Kashiwada; Masashi Hattori; Toshifumi Yamaguchi; Yoshiaki Shindo; Tetsuro Kawazoe; Sho Nambara; Yasuo Tsuda; Tomonori Nakanoko; Koji Ando; Tomoharu Yoshizumi; Kazuko Sakai; Kazuto Nishio; Eiji Oki
    International journal of clinical oncology  31  (8)  , 1597-1606, 26, May. 2026 

MORE

Books etc

  1. がんゲノム医療やさしい系統講義 , 松浦, 成昭; 櫻井, 晃洋; 石岡, 千加史; 西尾, 和人; 全国がんプロ協議会 , メディカル・サイエンス・インターナショナル , Apr. 2023
  2. liquid biopsy , Kazuto Nishio , 242-248 , 医学図書出版(株) , Aug. 2021
  3. Efficacy of EGFR tyrosine kinase inhibitors , Kazuto Nishio , 42-45 , ライフサイエンス出版(株) , 15, Jul. 2021

MORE

Conference Activities & Talks

  1. Latest Trends in Cancer Genome Research and Future Expectations for Biomarker Studies , Kazuto Nishio , Lung Cancer Leaders‘ サロン , 7, Jun. 2025
  2. Liquid Biopsy: Detecting Cancer Through Blood — The Astonishing Response of Platelets to the Tumor Microenvironment , Kazuto Nishio , ニットーボーメディカル オンラインセミナー , 31, Jan. 2025
  3. Advancements in Personalized Medicine through Cancer Proteogenomics , Kazuto Nishio , 日本プロテオーム学会2024年大会・第20回日本臨床プロテオゲノミクス学会 合同大会 , 28, Jun. 2024

MORE

MISC

  1. Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer. , Yusuke Kawanaka; Chiaki Inagaki; Masaki Okura; Seiichiro Mitani; Naoki Shiraishi; Kazuko Sakai; Kazuto Nishio; Yutaka Kimura; Yasutaka Chiba; Tomoko Wakasa; Hisato Kawakami; Hidetoshi Hayashi , International journal of clinical oncology , 98回 , 922 , 922 , 7, Jul. 2026
    Summary:BACKGROUND: CLDN18.2-targeted therapies show promise in HER2-negative, CLDN18.2-positive advanced gastric cancer (GC); however, cutoffs defining CLDN18.2 positivity vary across studies. Tumors with high expression (moderate to strong membranous expression in ≥ 75% of tumor cells) generally exhibit intratumoral homogeneity and a uniform staining pattern, but intratumoral heterogeneity and staining pattern of CLDN18.2 at lower expression thresholds remains unclear. This study investigated intratumoral heterogeneity of CLDN18.2 by comparing inter-block concordance of expression levels and staining patterns in GC. METHODS: Eighty-six resected GC specimens were retrospectively analyzed using CLDN18.2 immunohistochemistry on two tissue blocks per tumor. CLDN18.2 expression was categorized as high (≥ 75%), intermediate (< 75% and ≥ 40%), or negative (< 40%), and staining patterns as uniform or variable. Inter-block concordance of expression levels and staining patterns and their influence on concordance and outcomes were assessed. RESULTS: Overall inter-block concordance of expression levels was high (77%, κ = 0.89). Discordance was substantially higher in intermediate expression tumors (63.5%) than in high (15.5%) or negative (19%) expression tumors. Uniform staining was observed exclusively in high expression tumors, whereas all intermediate expression tumors displayed variable staining (100%). Among high expression tumors, inter-block concordance was substantially higher with uniform staining (98.0%) than with variable staining (71.5%). CLDN18.2 expression and staining pattern heterogeneity were not associated with worse survival. CONCLUSION: Significant intratumoral heterogeneity of CLDN18.2 expression was observed in GC, particularly in intermediate expression tumors; however, this heterogeneity does not affect survival. These results highlight the importance of standardized assessment methods when applying lower thresholds for CLDN18.2-targeted therapies.
  2. RBM10共変異を有するEGFR変異肺がん外科切除例の臨床病理学的特徴 , 須田 健一; 坂井 和子; 伊藤 正興; 老木 華; 福田 祥大; 小原 秀太; 濱田 顕; 千葉 眞人; 下治 正樹; 西尾 和人; 津谷 康大 , 日本呼吸器外科学会雑誌 , 40 , 3 , P53 , 2 , Apr. 2026
  3. PTPRRのダウンレギュレーションにより誘導されるEGFRの恒常的活性化はKRAS阻害薬耐性を付与する(Constitutive activation of EGFR induced by downregulation of PTPRR confers resistance to KRAS inhibitors) , 金村 宙昌; 竹原 俊幸; 前西 修; 冨田 秀太; 岩脇 菜摘; 國政 啓; 中山 智裕; 渡邊 諭美; 鈴木 慎一郎; 坂井 和子; 東 公一; 西尾 和人; 中川 和彦; 林 秀敏; 米阪 仁雄 , 肺癌 , 65 , 5 , 394 , 394 , Nov. 2025

MORE

Patents

  1. キット及び診断補助方法 , 星田 義彦, 宮本(辻井) 敦子, 徳永 勝士, 大前 陽輔, 西尾 和人, 坂井 和子
  2. 治療法の有利性を予見する予見方法 , 西尾 和人, 藤田 至彦 , 特許第6860148号
  3. がん治療のための併用療法としてのエリブリンとＳ−１（もしくは５−ＦＵ）の使用 , Kazuto Nishio , 特許第6644479号

MORE

Awards & Honors

  1. Mar. 2024, 第119回日本肺癌学会関西支部学術集会, haigan_kansai119th Best Presentation Award
  2. May. 2021, The 25th Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Takashi Tsuruo Award
  3. Dec. 2020, Japan Society of Clinical Proteogenomics, Japan Society of Clinical Proteogenomics Award

Research Grants & Projects

  1. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Innovative Development of Proteomic Technology for Predicting Postoperative Recurrence in Lung Cancer Using Tumor-Educated Platelets , Kindai University
  2. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Elucidating the molecular mechanisms of lung cancer recurrence through tight junctions, key cell&#8211;cell adhesion structures , Kindai University
  3. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Evaluation of minimal residual disease in postoperative lung cancer using platelet RNA influenced by the tumor environment. , Kindai University

MORE